104 related articles for article (PubMed ID: 15622758)
21. Voacamine, an alkaloid extracted from Peschiera fuchsiaefolia, inhibits P-glycoprotein action in multidrug-resistant tumor cells.
Meschini S; Marra M; Condello M; Calcabrini A; Federici E; Dupuis ML; Cianfriglia M; Arancia G
Int J Oncol; 2005 Dec; 27(6):1597-603. PubMed ID: 16273216
[TBL] [Abstract][Full Text] [Related]
22. Substituted tetrahydroisoquinoline compound B3 inhibited P-glycoprotein-mediated multidrug resistance in-vitro and in-vivo.
Fang W; Li Y; Cai Y; Kang K; Yan F; Liu G; Huang W
J Pharm Pharmacol; 2007 Dec; 59(12):1649-55. PubMed ID: 18053326
[TBL] [Abstract][Full Text] [Related]
23. [Overexpression of S3 ribosomal protein gene is involved in drug resistance in K562/DOX cells].
Zhu NX; Zheng S; Xu RZ; Yu RX
Zhonghua Xue Ye Xue Za Zhi; 2003 Mar; 24(3):141-3. PubMed ID: 12697126
[TBL] [Abstract][Full Text] [Related]
24. Proanthocyanidin from grape seeds enhances doxorubicin-induced antitumor effect and reverses drug resistance in doxorubicin-resistant K562/DOX cells.
Zhang XY; Li WG; Wu YJ; Bai DC; Liu NF
Can J Physiol Pharmacol; 2005 Mar; 83(3):309-18. PubMed ID: 15870845
[TBL] [Abstract][Full Text] [Related]
25. In vitro reversal MDR of human carcinoma cell line by an antisense oligodeoxynucleotide-doxorubicin conjugate.
Ren Y; Zhan X; Wei D; Liu J
Biomed Pharmacother; 2004 Nov; 58(9):520-6. PubMed ID: 15511610
[TBL] [Abstract][Full Text] [Related]
26. Induction of multidrug resistance in MOLT-4 cells by anticancer agents is closely related to increased expression of functional P-glycoprotein and MDR1 mRNA.
Liu ZL; Onda K; Tanaka S; Toma T; Hirano T; Oka K
Cancer Chemother Pharmacol; 2002 May; 49(5):391-7. PubMed ID: 11976833
[TBL] [Abstract][Full Text] [Related]
27. Modulation of P-glycoprotein-mediated multidrug resistance in K562 leukemic cells by indole-3-carbinol.
Arora A; Seth K; Kalra N; Shukla Y
Toxicol Appl Pharmacol; 2005 Feb; 202(3):237-43. PubMed ID: 15667829
[TBL] [Abstract][Full Text] [Related]
28. Multidrug (pleiotropic) resistance in doxorubicin-selected variants of the human sarcoma cell line MES-SA.
Harker WG; Sikic BI
Cancer Res; 1985 Sep; 45(9):4091-6. PubMed ID: 4028002
[TBL] [Abstract][Full Text] [Related]
29. Evaluation of anticancer effects of newly synthesized dihydropyridine derivatives in comparison to verapamil and doxorubicin on T47D parental and resistant cell lines in vitro.
Bazargan L; Fouladdel S; Shafiee A; Amini M; Ghaffari SM; Azizi E
Cell Biol Toxicol; 2008 Apr; 24(2):165-74. PubMed ID: 17805981
[TBL] [Abstract][Full Text] [Related]
30. Reduction of doxorubicin resistance by tetrandrine and dauricine in harringtonine-resistant human leukemia (HL60) cells.
He QY; Meng FH; Zhang HQ
Zhongguo Yao Li Xue Bao; 1996 Mar; 17(2):179-81. PubMed ID: 9772674
[TBL] [Abstract][Full Text] [Related]
31. Reversal effects of droloxifene on multidrug resistance in adriamycin-resistant K562 cell line.
Li J; Xu LZ; Yao JJ; Guo WJ; Xia P; Chen Y
Acta Pharmacol Sin; 2001 Nov; 22(11):1023-7. PubMed ID: 11749795
[TBL] [Abstract][Full Text] [Related]
32. Reversal effect of Ganoderma lucidum polysaccharide on multidrug resistance in K562/ADM cell line.
Li WD; Zhang BD; Wei R; Liu JH; Lin ZB
Acta Pharmacol Sin; 2008 May; 29(5):620-7. PubMed ID: 18430371
[TBL] [Abstract][Full Text] [Related]
33. Structure-activity relationships studies in a series of N,N-bis(alkanol)amine aryl esters as P-glycoprotein (Pgp) dependent multidrug resistance (MDR) inhibitors.
Martelli C; Coronnello M; Dei S; Manetti D; Orlandi F; Scapecchi S; Novella Romanelli M; Salerno M; Mini E; Teodori E
J Med Chem; 2010 Feb; 53(4):1755-62. PubMed ID: 20104851
[TBL] [Abstract][Full Text] [Related]
34. Sensitization and apoptosis augmentation of K562/ADM cells by anti-multidrug resistance gene peptide nucleic acid and antisense oligodeoxyribonucleotide.
Wei HL; Wu YJ; Jing T; Bai DC; Ma LF
Acta Pharmacol Sin; 2003 Aug; 24(8):805-11. PubMed ID: 12904281
[TBL] [Abstract][Full Text] [Related]
35. Liposome-based intracellular kinetics of doxorubicin in K562/DOX cells.
Xu DH; Gao JQ; Liang WQ
Pharmazie; 2008 Sep; 63(9):646-9. PubMed ID: 18819516
[TBL] [Abstract][Full Text] [Related]
36. Circumvention of tumor multidrug resistance by a new annonaceous acetogenin: atemoyacin-B.
Fu LW; Pan QC; Liang YJ; Huang HB
Zhongguo Yao Li Xue Bao; 1999 May; 20(5):435-9. PubMed ID: 10678092
[TBL] [Abstract][Full Text] [Related]
37. Reversal of p-glycoprotein-mediated multidrug resistance by CJX1, an amlodipine derivative, in doxorubicin-resistant human myelogenous leukemia (K562/DOX) cells.
Ji BS; He L; Liu GQ
Life Sci; 2005 Sep; 77(18):2221-32. PubMed ID: 15967469
[TBL] [Abstract][Full Text] [Related]
38. 2-Methoxyestradiol and multidrug resistance: can 2-methoxyestradiol chemosensitize resistant breast cancer cells?
Azab SS; Salama SA; Abdel-Naim AB; Khalifa AE; El-Demerdash E; Al-Hendy A
Breast Cancer Res Treat; 2009 Jan; 113(1):9-19. PubMed ID: 18228136
[TBL] [Abstract][Full Text] [Related]
39. Rhinacanthin-C enhances doxorubicin cytotoxicity via inhibiting the functions of P-glycoprotein and MRP2 in breast cancer cells.
Chaisit T; Siripong P; Jianmongkol S
Eur J Pharmacol; 2017 Jan; 795():50-57. PubMed ID: 27916559
[TBL] [Abstract][Full Text] [Related]
40. [Reversal effect and its mechanism of ampelopsin on multidrug resistance in K562/ADR cells].
Ye J; Zheng Y; Liu D
Zhongguo Zhong Yao Za Zhi; 2009 Mar; 34(6):761-5. PubMed ID: 19624024
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
